Form 4: Perspective Therapeutics CEO Acquires Shares in Open Market
SEC Form 4 Filing
Perspective Therapeutics CEO, Johan M. Spoor, purchased shares of the company's common stock in multiple transactions on November 25, 2024.
Summary
- Johan M. Spoor, CEO of Perspective Therapeutics, Inc., acquired 14,500 shares of common stock at a weighted average price of $3.784 per share on November 25, 2024.
- These shares were purchased in multiple transactions with prices ranging from $3.645 to $3.80 per share.
- Mr. Spoor also acquired 5,400 shares at $3.8 per share through his IRA and 6,600 shares at $3.8 per share through his spouse's IRA.
- Additionally, 10,000 shares are held indirectly by a child of Mr. Spoor.
- Following these transactions, Mr. Spoor directly owns 152,072 shares and indirectly owns 72,000 shares through his and his spouse's IRAs.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the CEO's purchase of shares suggests confidence in the company, but it's a routine transaction and not a major event.
Positives
- The CEO's purchase of shares may indicate confidence in the company's future prospects.
- The CEO's purchase of shares may be seen as a positive signal to the market.
Industry Context
Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's view of the company's prospects. This purchase by the CEO is a common occurrence and is not unusual.
Comparison to Industry Standards
- Insider buying is a common practice across the industry, with executives often purchasing shares in their own companies.
- The size of the transaction is not unusual for a CEO of a company of this size.
- The price range of the transactions is within the normal range for open market purchases.
Stakeholder Impact
- The share purchase may positively influence shareholder confidence.
- The share purchase may have a minor positive impact on the share price.
Key Dates
| Date | Description |
|---|---|
| 11/25/2024 | Date of the share purchase transactions by Johan M. Spoor. |
| 11/26/2024 | Date of signature for the SEC Form 4 filing. |
Keywords
insider trading, share acquisition, CEO, common stock, Perspective Therapeutics, CATX, Johan M. Spoor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.